Why Champion Iron, Dusk, Hipages, and Imugene shares are charging higher

These ASX shares are on fire on Friday…

| More on:
Concept image of a businessman riding a bull on an upwards arrow.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is rebounding strongly from recent declines. At the time of writing, the benchmark index is up 2.3% to 6,994.7 points.

Four ASX shares that are climbing more than most today are listed below. Here's why they are charging higher:

Champion Iron Ltd (ASX: CIA)

The Champion Iron share price is up 7% to $6.25. This follows a positive reaction to the iron ore producer's quarterly update from a number of brokers. One of those brokers is Citi. This morning the broker retained its buy rating and lifted its price target on the company's shares to $6.50. Citi was pleased with its quarterly update and has adjusted its estimates to reflect stronger iron ore prices.

Dusk Group Ltd (ASX: DSK)

The Dusk share price is up 14% to $2.70. Investors have been buying the retailer's shares following the release of a bullish broker note out of Shaw & Partners. According to the note, the broker has retained its buy rating and lifted its price target on the company's shares to $3.70.

Hipages Group Holdings Ltd (ASX: HPG)

The Hipages share price is up 7.5% to $3.00. Investors have been buying the tradie marketplace provider's shares after Goldman Sachs reaffirmed its buy rating on them following a disappointing quarterly update. The broker believes the soft quarter was a one-off due to COVID impacts and nothing structural. Goldman has a $3.60 price target on its shares.

Imugene Limited (ASX: IMU)

The Imugene share price is up 9% to 31.2 cents following the receipt of a patent. According to the release, the immuno-oncology company has received a notice of grant from the European Patent Office for its HER-Vaxx immunotherapy. This is currently in development for HER-2 positive gastric cancer.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns and has recommended Hipages Group Holdings Ltd. The Motley Fool Australia owns and has recommended Hipages Group Holdings Ltd. The Motley Fool Australia has recommended Dusk Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Gainers

Winning woman smiles and holds big cup while losing woman looks unhappy with small cup
Share Gainers

Here are the top 10 ASX 200 shares today

It was a dour Tuesday for ASX investors.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Brightstar Resources, Immutep, Pilbara Minerals, and Race Oncology shares are roaring higher

These shares are having a strong session on Tuesday. But why?

Read more »

A graphic of a pink rocket taking off above an increasing chart.
Healthcare Shares

Guess which ASX 300 healthcare share is rocketing 28% on global expansion news

Investors are piling into the ASX 300 healthcare share on Tuesday. Let’s see why.

Read more »

A neon sign says 'Top Ten'.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a Garfield kind of Monday for investors.

Read more »

Happy shareholders clap and smile as they listen to a company earnings report.
Share Gainers

Why Artrya, Clinuvel, Imugene, and Pilbara Minerals shares are storming higher today

These shares are starting the week in a positive fashion. But why?

Read more »

An old-fashioned panel of judges each holding a card with the number 10
Share Gainers

Here are the top 10 ASX 200 shares today

It was a happy end to the trading week this Friday.

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Up 680% since July, here's why 2025 was a breakout year for this hot ASX stock

With consistent contract wins, FDA clearance, and backing from Pro Medicus, 4D Medical is showing that there is a commercial…

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors have been piling into these four ASX 200 stocks this week. Let’s see why.

Read more »